HRP980187B1 - Influenza vaccine - Google Patents

Influenza vaccine

Info

Publication number
HRP980187B1
HRP980187B1 HR980187A HRP980187A HRP980187B1 HR P980187 B1 HRP980187 B1 HR P980187B1 HR 980187 A HR980187 A HR 980187A HR P980187 A HRP980187 A HR P980187A HR P980187 B1 HRP980187 B1 HR P980187B1
Authority
HR
Croatia
Prior art keywords
influenza vaccine
influenza
vaccine
Prior art date
Application number
HR980187A
Other languages
English (en)
Inventor
Gustaaf J M Van Scharrenburg
Rudi Brands
Original Assignee
Duphar Int Res
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8228174&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HRP980187(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Duphar Int Res filed Critical Duphar Int Res
Publication of HRP980187A2 publication Critical patent/HRP980187A2/hr
Publication of HRP980187B1 publication Critical patent/HRP980187B1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16051—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16211—Influenzavirus B, i.e. influenza B virus
    • C12N2760/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Pulmonology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
HR980187A 1997-04-09 1998-04-06 Influenza vaccine HRP980187B1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP97201007 1997-04-09

Publications (2)

Publication Number Publication Date
HRP980187A2 HRP980187A2 (en) 1999-04-30
HRP980187B1 true HRP980187B1 (en) 2001-04-30

Family

ID=8228174

Family Applications (1)

Application Number Title Priority Date Filing Date
HR980187A HRP980187B1 (en) 1997-04-09 1998-04-06 Influenza vaccine

Country Status (32)

Country Link
US (1) US5948410A (xx)
EP (1) EP0870508B1 (xx)
JP (1) JP5258127B2 (xx)
KR (1) KR100593235B1 (xx)
CN (1) CN1138564C (xx)
AR (1) AR011216A1 (xx)
AT (1) ATE197406T1 (xx)
AU (1) AU728939B2 (xx)
BR (1) BR9801015A (xx)
CA (1) CA2234208C (xx)
CZ (1) CZ297492B6 (xx)
DE (2) DE870508T1 (xx)
DK (1) DK0870508T3 (xx)
DZ (1) DZ2462A1 (xx)
ES (1) ES2129386T3 (xx)
GR (2) GR990300017T1 (xx)
HK (1) HK1010833A1 (xx)
HR (1) HRP980187B1 (xx)
HU (1) HUP9800802A3 (xx)
ID (1) ID20399A (xx)
IL (1) IL123961A (xx)
NO (1) NO323349B1 (xx)
NZ (1) NZ330131A (xx)
PL (1) PL187982B1 (xx)
PT (1) PT870508E (xx)
RU (1) RU2197264C2 (xx)
SI (1) SI0870508T1 (xx)
SK (1) SK282614B6 (xx)
TR (1) TR199800613A1 (xx)
TW (1) TW570803B (xx)
UA (1) UA42089C2 (xx)
ZA (1) ZA982915B (xx)

Families Citing this family (99)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ517903A (en) * 1999-09-24 2003-10-31 Smithkline Beecham Biolog S One dose intranasal influenza virus vaccine with split influenza viral antigens
GB9923176D0 (en) * 1999-09-30 1999-12-01 Smithkline Beecham Biolog Novel composition
CN100415769C (zh) * 2002-02-07 2008-09-03 中国科学院过程工程研究所 寡聚或多聚亚基蛋白质分离纯化的方法
AU2003229159B2 (en) 2002-04-30 2008-02-21 Oncolytics Biotech Inc. Improved viral purification methods
US20060110406A1 (en) 2003-02-25 2006-05-25 Medimmune Vaccines, Inc. Refrigerator-temperature stable influenza vaccine compositions
EP1597400B8 (en) * 2003-02-25 2013-10-09 MedImmune, LLC Methods of producing influenza vaccine compositions
DE602004028736D1 (de) * 2003-06-20 2010-09-30 Microbix Biosystems Inc Verbesserungen bei der virusproduktion
US8506967B2 (en) 2003-07-11 2013-08-13 Novavax, Inc. Functional influenza virus like particles (VLPs)
US8592197B2 (en) 2003-07-11 2013-11-26 Novavax, Inc. Functional influenza virus-like particles (VLPs)
US8992939B2 (en) 2003-07-11 2015-03-31 Novavax, Inc. Highly efficient influenza matrix (M1) proteins
US8080255B2 (en) 2003-07-11 2011-12-20 Novavax Inc. Functional influenza virus like particles (VLPs)
AU2005214090B2 (en) 2004-02-23 2008-09-11 Crucell Holland B.V. Virus purification methods
EP1722815A1 (en) 2004-03-09 2006-11-22 Chiron Corporation Influenza virus vaccines
EP2471551B1 (en) 2004-09-09 2017-02-01 Novartis AG Decreasing potential iatrogenic risks associated with influenza vaccines
US7901921B2 (en) 2004-10-22 2011-03-08 Oncolytics Biotech Inc. Viral purification methods
US20090004222A1 (en) 2004-11-03 2009-01-01 O'hagan Derek Influenza Vaccination
EP2368975B1 (en) 2004-12-23 2014-09-17 MedImmune, LLC Non-tumorigenic MDCK cell line for propagating viruses
TW200700078A (en) 2005-03-23 2007-01-01 Glaxosmithkline Biolog Sa Novel use
CA2602944C (en) * 2005-04-11 2015-08-11 Crucell Holland B.V. Virus purification using ultrafiltration
ATE494906T1 (de) * 2005-11-01 2011-01-15 Novartis Vaccines & Diagnostic Von zellen stammende virale impfstoffe mit geringen mengen an rest-zell-dna
US11707520B2 (en) 2005-11-03 2023-07-25 Seqirus UK Limited Adjuvanted vaccines with non-virion antigens prepared from influenza viruses grown in cell culture
AU2006310163B2 (en) 2005-11-04 2011-09-15 Seqirus UK Limited Influenza vaccine with reduced amount of oil-in-water emulsion as adjuvant
PT1951299E (pt) 2005-11-04 2012-02-28 Novartis Vaccines & Diagnostic Vacinas contra a gripe que incluem combinações de adjuvantes particulados e imuno-potenciadores
NZ568210A (en) * 2005-11-04 2012-12-21 Novartis Vaccines & Diagnostic Emulsions with free aqueous-phase surfactant as adjuvants for split influenza vaccines
HUE051122T2 (hu) * 2005-11-04 2021-03-01 Seqirus Uk Ltd Sejttenyészetben növesztett influenzavírusból elõállított nemvirion anti-géneket tartalmazó adjuvált vakcinák
CN102755645A (zh) 2005-11-04 2012-10-31 诺华疫苗和诊断有限公司 佐剂配制的包含细胞因子诱导剂的流感疫苗
EP1976559B3 (en) 2006-01-27 2020-02-19 Seqirus UK Limited Influenza vaccines containing hemagglutinin and matrix proteins
WO2007110776A1 (en) 2006-03-24 2007-10-04 Novartis Vaccines And Diagnostics Gmbh & Co Kg Storage of influenza vaccines without refrigeration
WO2007126810A2 (en) 2006-03-31 2007-11-08 Warf - Wisconsin Alumni Research Foundation High titer recombinant influenza viruses for vaccines
PL2043682T3 (pl) 2006-07-17 2014-09-30 Glaxosmithkline Biologicals Sa Szczepionka przeciw grypie
GB0614460D0 (en) * 2006-07-20 2006-08-30 Novartis Ag Vaccines
WO2008032219A2 (en) 2006-09-11 2008-03-20 Novartis Ag Making influenza virus vaccines without using eggs
AU2007347716B2 (en) 2006-09-15 2013-06-20 Medimmune, Llc MDCK cell lines supporting viral growth to high titers and bioreactor process using the same
EP2532362A1 (en) 2006-12-06 2012-12-12 Novartis AG Vaccines including antigen from four strains of influenza virus
US8697154B2 (en) * 2007-03-05 2014-04-15 Om Pharma Sa Bacterial extract for respiratory disorders and process for its preparation
CA2680600A1 (en) 2007-03-12 2008-09-18 Antigen Express, Inc. Li-rnai involved li suppression in cancer immunotherapy
AR066405A1 (es) 2007-04-20 2009-08-19 Glaxosmithkline Biolog Sa Vacuna
US9474798B2 (en) 2007-06-18 2016-10-25 Wisconsin Alumni Research Foundation Influenza M2 protein mutant viruses as live influenza attenuated vaccines
PT2185191E (pt) 2007-06-27 2012-11-27 Novartis Ag Vacinas contra a gripe com baixo teor de aditivos
CA2697373C (en) * 2007-08-27 2019-05-21 Longhorn Vaccines & Diagnostics, Llc Immunogenic compositions and methods
GB0810305D0 (en) 2008-06-05 2008-07-09 Novartis Ag Influenza vaccination
CA2718430A1 (en) 2008-03-18 2009-09-24 Novartis Ag Improvements in preparation of influenza virus vaccine antigens
WO2010036760A1 (en) * 2008-09-24 2010-04-01 Medimmune, Llc Methods for cultivating cells, propagating and purifying viruses
WO2010052214A2 (en) 2008-11-05 2010-05-14 Glaxosmithkline Biologicals S.A. Novel method
EA201171032A1 (ru) 2009-02-10 2012-02-28 Новартис Аг Схемы лечения с помощью вакцины против гриппа, связанного с пандемическими штаммами
CA2752041A1 (en) 2009-02-10 2010-08-19 Novartis Ag Influenza vaccines with increased amounts of h3 antigen
EP2396032B1 (en) 2009-02-10 2016-09-28 Seqirus UK Limited Influenza vaccines with reduced amounts of squalene
CN102548577A (zh) 2009-04-27 2012-07-04 诺华有限公司 用于抵抗流感的佐剂疫苗
AU2010250832B2 (en) 2009-05-21 2013-10-03 Seqirus UK Limited Reverse genetics using non-endogenous pol I promoters
WO2010144797A2 (en) 2009-06-12 2010-12-16 Vaccine Technologies, Incorporated Influenza vaccines with enhanced immunogenicity and uses thereof
CA2803282C (en) 2009-07-06 2018-05-01 David E. Anderson Methods for preparing vesicles and formulations produced therefrom
CN102482666B (zh) 2009-07-06 2017-02-08 变异生物技术公司 制备囊泡的方法和由其产生的制剂
CA2769673A1 (en) 2009-07-31 2011-02-03 Novartis Ag Reverse genetics systems
WO2011030218A1 (en) 2009-09-10 2011-03-17 Novartis Ag Combination vaccines against respiratory tract diseases
CN102741399A (zh) 2009-10-20 2012-10-17 诺华有限公司 用于病毒拯救的改良反向遗传方法
EP2493912B1 (en) 2009-10-26 2020-07-29 Wisconsin Alumni Research Foundation High titer recombinant influenza viruses with enhanced replication in vero cells
US10130697B2 (en) 2010-03-23 2018-11-20 Wisconsin Alumni Research Foundation (Warf) Vaccines comprising mutant attenuated influenza viruses
AU2011254204B2 (en) 2010-05-21 2015-08-20 Seqirus UK Limited Influenza virus reassortment method
CN103096921A (zh) 2010-06-01 2013-05-08 诺华有限公司 不用冻干疫苗抗原浓缩
JP5976639B2 (ja) 2010-06-01 2016-08-23 ノバルティス アーゲー インフルエンザワクチン抗原の濃縮および凍結乾燥
US9610248B2 (en) 2010-07-06 2017-04-04 Variation Biotechnologies, Inc. Compositions and methods for treating influenza
CA2808965C (en) 2010-08-20 2020-01-07 Novartis Ag Soluble needle arrays for delivery of influenza vaccines
CA2862871C (en) 2011-01-13 2020-09-22 Variation Biotechnologies Inc. Methods for preparing vesicles and formulations produced therefrom
EP2663327A4 (en) 2011-01-13 2015-12-02 Variation Biotechnologies Inc COMPOSITIONS AND METHOD FOR THE TREATMENT OF VIRUS INFECTIONS
US20140248320A1 (en) 2011-10-20 2014-09-04 Novartis Ag Adjuvanted influenza b virus vaccines for pediatric priming
US20140328876A1 (en) 2011-11-18 2014-11-06 Variation Biotechnologies Inc. Synthetic derivatives of mpl and uses thereof
CN104302323A (zh) 2012-01-12 2015-01-21 变异生物技术公司 用于治疗病毒感染的组合物和方法
CA2894467A1 (en) 2012-01-27 2013-08-01 Variation Biotechnologies Inc. Methods for preparing thermostable compositions comprising a lipid component and thermolabile therapeutic agents
AU2013205478B9 (en) 2012-03-02 2014-11-20 Seqirus UK Limited Influenza virus reassortment
AU2013270793A1 (en) 2012-06-04 2014-12-11 Novartis Ag Improved safety testing
GB201218195D0 (en) 2012-10-10 2012-11-21 Istituto Zooprofilattico Sperimentale Delle Venezie Composition
EP2925356A2 (en) 2012-12-03 2015-10-07 Novartis AG Reassortant influenza a viren
CA2905612A1 (en) 2013-03-13 2014-09-18 Novartis Ag Influenza virus reassortment
CN105828835A (zh) 2013-05-10 2016-08-03 诺华股份有限公司 避免流感疫苗中的发作性嗜睡病风险
DE202013005100U1 (de) 2013-06-05 2013-08-26 Novartis Ag Influenza Virus Reassortierung
DE202013005130U1 (de) 2013-06-05 2013-09-10 Novartis Ag Influenza Virus Reassortierung
CA2914604A1 (en) 2013-06-06 2014-12-11 Novartis Ag Influenza virus reassortment
WO2015009743A1 (en) 2013-07-15 2015-01-22 Wisconsin Alumni Research Foundation High titer recombinant influenza viruses with enhanced replication in mdck or vero cells or eggs
RU2535153C1 (ru) * 2013-09-04 2014-12-10 Федеральное государственное унитарное предприятие "Санкт-Петербургский научно-исследовательский институт вакцин и сывороток и предприятие по производству бактерийных препаратов" Федерального медико-биологического агентства России (ФГУП СПбНИИВС ФМБА России) Способ получения высокоочищенных вирионных концентратов
CN105745218B (zh) 2013-11-15 2020-11-06 诺华股份有限公司 去除残留细胞培养杂质
WO2015196150A2 (en) 2014-06-20 2015-12-23 Wisconsin Alumni Research Foundation (Warf) Mutations that confer genetic stability to additional genes in influenza viruses
EP2966093A1 (en) 2014-07-07 2016-01-13 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Process for the preparation of magnetic sulfated cellulose particles, magnetic sulfated cellulose particles and their use
US10633422B2 (en) 2015-06-01 2020-04-28 Wisconsin Alumni Research Foundation (Warf) Influenza virus replication by inhibiting microRNA lec7C binding to influenza viral cRNA and mRNA
RU2614127C2 (ru) * 2015-06-04 2017-03-22 Общество с ограниченной ответственностью "НТфарма" Способ получения концентрата рекомбинантных псевдоаденовирусных частиц, экспрессирующих ген гемагглютинина вируса гриппа A/California/07/2009(H1N1)
BR112017028011A2 (pt) 2015-06-26 2018-08-28 Seqirus Uk Ltd vacinas de gripe correspondentes antigenicamente
WO2017007839A1 (en) 2015-07-06 2017-01-12 Wisconsin Alumni Research Foundation (Warf) Improved influenza virus replication for vaccine development
BR112018000296A2 (pt) 2015-07-07 2018-09-04 Seqirus UK Limited ensaios de potência de influenza
CN109477074B (zh) 2016-02-19 2023-01-24 威斯康星旧生研究基金会 用于疫苗开发的改进的乙型流感病毒复制
EP3601544A4 (en) 2017-03-30 2021-01-27 Merck Sharp & Dohme Corp. ADDITION OF NUCLEASES DIRECTLY TO CELL CULTURE TO FACILITATE DIGESTION AND CLEARANCE OF NUCLEIC ACIDS FROM HOST CELLS
RU2670001C1 (ru) * 2017-12-25 2018-10-17 Федеральное государственное бюджетное учреждение науки Институт биохимии и физиологии растений и микроорганизмов Российской академии наук Способ получения белков клеточной поверхности
AU2019207600A1 (en) 2018-01-09 2020-07-09 Theriva Biologics, Inc. Alkaline phosphatase agents for treatment of neurodevelopmental disorders
WO2019183209A1 (en) 2018-03-20 2019-09-26 Synthetic Biologics, Inc. Alkaline phosphatase agents for treatment of radiation disorders
WO2019183208A1 (en) 2018-03-20 2019-09-26 Synthetic Biologics, Inc. Intestinal alkaline phosphatase formulations
WO2020167432A2 (en) 2019-01-23 2020-08-20 Yoshihiro Kawaoka Mutations that confer genetic stability to additional genes in influenza viruses
EP3921413A1 (en) 2019-02-08 2021-12-15 Wisconsin Alumni Research Foundation (WARF) Humanized cell line
WO2020223699A1 (en) 2019-05-01 2020-11-05 Wisconsin Alumni Research Foundation (Warf) Improved influenza virus replication for vaccine development
US11807872B2 (en) 2019-08-27 2023-11-07 Wisconsin Alumni Research Foundation (Warf) Recombinant influenza viruses with stabilized HA for replication in eggs
US20230000971A1 (en) 2019-11-18 2023-01-05 Seqirus Pty Ltd. Method for producing reassortant influenza viruses
KR102444684B1 (ko) * 2020-04-29 2022-09-16 에스케이바이오사이언스(주) 일회용 배양 공정 시스템을 이용한 인플루엔자 바이러스 생산 방법

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH589453A5 (xx) * 1974-01-14 1977-07-15 Sandoz Ag
US4500513A (en) * 1979-05-15 1985-02-19 Miles Laboratories, Inc. Influenza vaccine production in liquid cell culture
US4317811A (en) * 1980-09-11 1982-03-02 Merck & Co., Inc. Herpes simplex type 1 subunit vaccine
DE3237313A1 (de) * 1982-10-08 1984-04-12 Werner Heese Verfahren zur gewinnung und reinigung antigenhaltiger loesungen, insbesondere fuer influenza-viren, aus antigenhaltiger allantoisfluessigkeit
US4783411A (en) * 1984-10-22 1988-11-08 Janis Gabliks Influenza-A virus vaccine from fish cell cultures
US5173418A (en) * 1985-05-10 1992-12-22 Benzon Pharma, A/S Production in Escherichia coli of extracellular Serratia spp. hydrolases
US5006472A (en) * 1988-06-03 1991-04-09 Miles Inc. Enzymatic purification process
RU2080876C1 (ru) * 1989-02-07 1997-06-10 Био-Текнолоджи Дженерал Корп. Способ получения очищенных частиц поверхностного антигена гепатита в, очищенная частица поверхностного антигена гепатита в человека и вакцина против гепатита в
ATE132160T1 (de) * 1989-03-29 1996-01-15 Univ New York State Res Found Verfahren zur reinigung von aussenmembran-protein von haemophilus influenza
DZ1706A1 (fr) * 1992-08-07 2002-02-17 Merck & Co Inc Vaccin contre le virus de l'hepatite a.
HRP950097A2 (en) * 1994-03-08 1997-06-30 Merck & Co Inc Hepatitis a virus culture process
WO1996015231A2 (en) * 1994-11-10 1996-05-23 Immuno Aktiengesellschaft Method for producing biologicals in protein-free culture
US5681746A (en) * 1994-12-30 1997-10-28 Chiron Viagene, Inc. Retroviral delivery of full length factor VIII
WO1997004803A1 (fr) * 1995-08-01 1997-02-13 Pasteur Merieux Serums & Vaccins Procede de production industrielle d'un vaccin contre l'encephalite japonaise et vaccin obtenu
WO1997011605A1 (en) * 1995-09-28 1997-04-03 University Of Pittsburgh Of The Commonwealth System Of Higher Education Stimulation of cell-mediated immune responses by targeted particulate genetic immunization

Also Published As

Publication number Publication date
NO981557L (no) 1998-10-12
CA2234208C (en) 2003-06-10
PT870508E (pt) 2001-04-30
ES2129386T3 (es) 2001-01-01
CN1138564C (zh) 2004-02-18
SK44598A3 (en) 1998-11-04
AU6065998A (en) 1998-10-15
HUP9800802A2 (hu) 1999-04-28
DK0870508T3 (da) 2000-11-20
IL123961A (en) 2000-07-16
JPH1121253A (ja) 1999-01-26
JP5258127B2 (ja) 2013-08-07
HUP9800802A3 (en) 2003-08-28
DE69800383D1 (de) 2000-12-14
DZ2462A1 (fr) 2003-01-18
SI0870508T1 (en) 2001-02-28
NO323349B1 (no) 2007-04-02
EP0870508A1 (en) 1998-10-14
KR100593235B1 (ko) 2007-12-04
GR3034798T3 (en) 2001-02-28
DE870508T1 (de) 1999-08-19
AU728939B2 (en) 2001-01-18
KR19980081114A (ko) 1998-11-25
ES2129386T1 (es) 1999-06-16
BR9801015A (pt) 2000-01-11
HRP980187A2 (en) 1999-04-30
ID20399A (id) 1998-12-10
NO981557D0 (no) 1998-04-06
DE69800383T2 (de) 2001-08-16
GR990300017T1 (en) 1999-06-30
ZA982915B (en) 1999-01-21
UA42089C2 (uk) 2001-10-15
AR011216A1 (es) 2000-08-02
NZ330131A (en) 1999-10-28
PL187982B1 (pl) 2004-11-30
RU2197264C2 (ru) 2003-01-27
EP0870508B1 (en) 2000-11-08
CN1196956A (zh) 1998-10-28
PL325722A1 (en) 1998-10-12
HU9800802D0 (en) 1998-05-28
ATE197406T1 (de) 2000-11-11
TW570803B (en) 2004-01-11
CZ297492B6 (cs) 2007-01-03
MX9802766A (es) 1998-12-31
SK282614B6 (sk) 2002-10-08
HK1010833A1 (en) 1999-07-02
US5948410A (en) 1999-09-07
CZ105098A3 (cs) 1998-10-14
TR199800613A1 (xx) 1998-10-21
CA2234208A1 (en) 1998-10-09

Similar Documents

Publication Publication Date Title
ZA982915B (en) Influenza vaccine
GB9712347D0 (en) Vaccine
GB9718901D0 (en) Vaccine
IL136447A0 (en) Vaccine
GB9711990D0 (en) Vaccine
GB9726555D0 (en) Vaccine
GB9720585D0 (en) Vaccine
AU1308495A (en) Influenza vaccine
EP1083926A4 (en) VACCINE
IL132121A0 (en) Leishmania vaccine
GB0027072D0 (en) Vaccine
ZA982763B (en) Vaccines
GB9702990D0 (en) Virus vaccine
GB9718616D0 (en) Oral vaccine
GB9718902D0 (en) Vaccine
GB9720982D0 (en) Vaccine
GB9717423D0 (en) Vaccine
GB9725241D0 (en) Hiv vaccine
GB9703202D0 (en) HIV vaccine
GB9702920D0 (en) Vaccines
GB9701200D0 (en) Targeted allergy vaccine
GB9805962D0 (en) Vaccine
GB9802543D0 (en) Vaccine
GB9802544D0 (en) Vaccine
GB9802650D0 (en) Vaccine

Legal Events

Date Code Title Description
A1OB Publication of a patent application
AIPI Request for the grant of a patent on the basis of a substantive examination of a patent application
B1PR Patent granted
PPPP Transfer of rights

Owner name: SOLVAY BIOLOGICALS B.V., NL

PNAN Change of the applicant name, address/residence

Owner name: ABBOTT BIOLOGICALS B.V., NL

PPPP Transfer of rights

Owner name: BGP PRODUCTS B.V., NL

ODRP Renewal fee for the maintenance of a patent

Payment date: 20170404

Year of fee payment: 20

PB20 Patent expired after termination of 20 years

Effective date: 20180406